JPS6333326A - Antibacterial composition - Google Patents
Antibacterial compositionInfo
- Publication number
- JPS6333326A JPS6333326A JP61177968A JP17796886A JPS6333326A JP S6333326 A JPS6333326 A JP S6333326A JP 61177968 A JP61177968 A JP 61177968A JP 17796886 A JP17796886 A JP 17796886A JP S6333326 A JPS6333326 A JP S6333326A
- Authority
- JP
- Japan
- Prior art keywords
- antibacterial
- bisabolol
- component
- acid
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims abstract description 33
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims abstract description 32
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229940036350 bisabolol Drugs 0.000 claims abstract description 20
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000013543 active substance Substances 0.000 claims description 20
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 abstract description 20
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 abstract description 10
- 229960004889 salicylic acid Drugs 0.000 abstract description 10
- 239000000126 substance Substances 0.000 abstract description 7
- 239000000645 desinfectant Substances 0.000 abstract description 5
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 abstract description 5
- 229960004068 hexachlorophene Drugs 0.000 abstract description 5
- 235000007866 Chamaemelum nobile Nutrition 0.000 abstract description 4
- 235000007232 Matricaria chamomilla Nutrition 0.000 abstract description 4
- 206010040880 Skin irritation Diseases 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 230000036556 skin irritation Effects 0.000 abstract description 4
- 231100000475 skin irritation Toxicity 0.000 abstract description 4
- 208000035473 Communicable disease Diseases 0.000 abstract description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract description 2
- 210000000214 mouth Anatomy 0.000 abstract description 2
- 239000011734 sodium Substances 0.000 abstract description 2
- 229910052708 sodium Inorganic materials 0.000 abstract description 2
- 229940083542 sodium Drugs 0.000 abstract description 2
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 abstract 1
- 240000003538 Chamaemelum nobile Species 0.000 abstract 1
- 241000192125 Firmicutes Species 0.000 abstract 1
- 229960005443 chloroxylenol Drugs 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 244000005700 microbiome Species 0.000 abstract 1
- -1 Salicylic acid 8-benzoxyquinoline Chemical compound 0.000 description 19
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 description 12
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 239000004166 Lanolin Substances 0.000 description 7
- 229940039717 lanolin Drugs 0.000 description 7
- 235000019388 lanolin Nutrition 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- OJFZXRZZXBFEAP-UHFFFAOYSA-N 5-chloro-1,6-dimethylcyclohexa-2,4-dien-1-ol Chemical compound ClC=1C(C(C=CC1)(C)O)C OJFZXRZZXBFEAP-UHFFFAOYSA-N 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 5
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 208000022196 parasitic skin disease Diseases 0.000 description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 4
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 4
- 239000003871 white petrolatum Substances 0.000 description 4
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 244000042664 Matricaria chamomilla Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 229940092738 beeswax Drugs 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 3
- 229960004880 tolnaftate Drugs 0.000 description 3
- 229960002703 undecylenic acid Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 description 2
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- SODWJACROGQSMM-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalen-1-amine Chemical compound C1CCCC2=C1C=CC=C2N SODWJACROGQSMM-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010021531 Impetigo Diseases 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 241001358150 Myrocarpus Species 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 229920001800 Shellac Polymers 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000005844 Thymol Substances 0.000 description 2
- FDODMJVLXHAZON-UHFFFAOYSA-M Trimethylcetylammonium pentachlorophenate Chemical compound [O-]C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl.CCCCCCCCCCCCCCCC[N+](C)(C)C FDODMJVLXHAZON-UHFFFAOYSA-M 0.000 description 2
- ZYPGADGCNXOUJP-CXVPHVKISA-N Variotin Chemical compound CCCC[C@@H](O)\C=C(/C)\C=C\C=C\C(=O)N1CCCC1=O ZYPGADGCNXOUJP-CXVPHVKISA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 229940119217 chamomile extract Drugs 0.000 description 2
- 235000020221 chamomile extract Nutrition 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229960003993 chlorphenesin Drugs 0.000 description 2
- 229960004022 clotrimazole Drugs 0.000 description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- ZYPGADGCNXOUJP-UHFFFAOYSA-N dl-Variotin Natural products CCCCC(O)C=C(C)C=CC=CC(=O)N1CCCC1=O ZYPGADGCNXOUJP-UHFFFAOYSA-N 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 229960003645 econazole nitrate Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- CKSJXOVLXUMMFF-UHFFFAOYSA-N exalamide Chemical compound CCCCCCOC1=CC=CC=C1C(N)=O CKSJXOVLXUMMFF-UHFFFAOYSA-N 0.000 description 2
- 229950010333 exalamide Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N iodoform Chemical compound IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229960005040 miconazole nitrate Drugs 0.000 description 2
- 238000011169 microbiological contamination Methods 0.000 description 2
- 229960000988 nystatin Drugs 0.000 description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 235000010292 orthophenyl phenol Nutrition 0.000 description 2
- 239000004306 orthophenyl phenol Substances 0.000 description 2
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachlorophenol Chemical compound OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 229940055019 propionibacterium acne Drugs 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000004208 shellac Substances 0.000 description 2
- 235000013874 shellac Nutrition 0.000 description 2
- 229940113147 shellac Drugs 0.000 description 2
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 2
- 239000004328 sodium tetraborate Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 229960000790 thymol Drugs 0.000 description 2
- GAAKLDANOSASAM-UHFFFAOYSA-N undec-10-enoic acid;zinc Chemical compound [Zn].OC(=O)CCCCCCCCC=C GAAKLDANOSASAM-UHFFFAOYSA-N 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 229940118257 zinc undecylenate Drugs 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WHRZCXAVMTUTDD-UHFFFAOYSA-N 1h-furo[2,3-d]pyrimidin-2-one Chemical compound N1C(=O)N=C2OC=CC2=C1 WHRZCXAVMTUTDD-UHFFFAOYSA-N 0.000 description 1
- XFOQWQKDSMIPHT-UHFFFAOYSA-N 2,3-dichloro-6-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)C(Cl)=N1 XFOQWQKDSMIPHT-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- NCLNAHJFXIKYBY-UHFFFAOYSA-N 2-hexyldecyl 16-methylheptadecanoate Chemical compound CCCCCCCCC(CCCCCC)COC(=O)CCCCCCCCCCCCCCC(C)C NCLNAHJFXIKYBY-UHFFFAOYSA-N 0.000 description 1
- LOIMOHMWAXGSLR-UHFFFAOYSA-N 2-hexyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCC LOIMOHMWAXGSLR-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- WADQOGCINABPRT-UHFFFAOYSA-N 3-chloro-2-methylphenol Chemical compound CC1=C(O)C=CC=C1Cl WADQOGCINABPRT-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010001557 Albinism Diseases 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- QFVAWNPSRQWSDU-UHFFFAOYSA-N Dibenzthion Chemical compound C1N(CC=2C=CC=CC=2)C(=S)SCN1CC1=CC=CC=C1 QFVAWNPSRQWSDU-UHFFFAOYSA-N 0.000 description 1
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 244000073231 Larrea tridentata Species 0.000 description 1
- 235000006173 Larrea tridentata Nutrition 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 241000282330 Procyon lotor Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 239000005843 Thiram Substances 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000012164 animal wax Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UDEWPOVQBGFNGE-UHFFFAOYSA-N benzoic acid n-propyl ester Natural products CCCOC(=O)C1=CC=CC=C1 UDEWPOVQBGFNGE-UHFFFAOYSA-N 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000019480 chamomile oil Nutrition 0.000 description 1
- 239000010628 chamomile oil Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960002126 creosote Drugs 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
- 229960002867 griseofulvin Drugs 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- GQXQIRNPJBUEGY-UHFFFAOYSA-N hexadecan-7-yl 2,2-dimethyloctanoate Chemical compound CCCCCCCCCC(CCCCCC)OC(=O)C(C)(C)CCCCCC GQXQIRNPJBUEGY-UHFFFAOYSA-N 0.000 description 1
- OIKBVOIOVNEVJR-UHFFFAOYSA-N hexadecyl 6-methylheptanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCC(C)C OIKBVOIOVNEVJR-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- AHXDSVSZEZHDLV-UHFFFAOYSA-N mesulfen Chemical compound CC1=CC=C2SC3=CC(C)=CC=C3SC2=C1 AHXDSVSZEZHDLV-UHFFFAOYSA-N 0.000 description 1
- 229960005479 mesulfen Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- OLXYLDUSSBULGU-UHFFFAOYSA-N methyl pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1 OLXYLDUSSBULGU-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229960001755 resorcinol Drugs 0.000 description 1
- WBHHMMIMDMUBKC-XLNAKTSKSA-N ricinelaidic acid Chemical compound CCCCCC[C@@H](O)C\C=C\CCCCCCCC(O)=O WBHHMMIMDMUBKC-XLNAKTSKSA-N 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 229960005076 sodium hypochlorite Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229960002999 sulbentine Drugs 0.000 description 1
- 229960005349 sulfur Drugs 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- KUAZQDVKQLNFPE-UHFFFAOYSA-N thiram Chemical compound CN(C)C(=S)SSC(=S)N(C)C KUAZQDVKQLNFPE-UHFFFAOYSA-N 0.000 description 1
- 229960002447 thiram Drugs 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- SLYPOVJCSQHITR-UHFFFAOYSA-N tioxolone Chemical compound OC1=CC=C2SC(=O)OC2=C1 SLYPOVJCSQHITR-UHFFFAOYSA-N 0.000 description 1
- 229960003070 tioxolone Drugs 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 229930188428 trichomycin Natural products 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- SVETUDAIEHYIKZ-IUPFWZBJSA-N tris[(z)-octadec-9-enyl] phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCCOP(=O)(OCCCCCCCC\C=C/CCCCCCCC)OCCCCCCCC\C=C/CCCCCCCC SVETUDAIEHYIKZ-IUPFWZBJSA-N 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明社抗菌剤組成物に関する0
〔従来の技術およびその問題点〕
従来、菌発育阻止作用を有する化合物(以下抗菌活性物
質という)は、寄生性皮膚疾患用剤や殺菌消毒剤の生薬
として配合され、あるいは防腐剤として広く利用されて
いる。[Detailed Description of the Invention] [Industrial Field of Application] 0 Regarding the Antibacterial Agent Composition of the Present Inventor [Prior Art and its Problems] Conventionally, compounds having a bacterial growth inhibiting effect (hereinafter referred to as antibacterial active substances) It is widely used as a herbal medicine for parasitic skin diseases and disinfectants, and as a preservative.
しかし、これらの抗菌活性物質は、皮膚等に適用された
場合刺激性を伴うことが多く、これらの刺激による皮膚
障害等の副作用を発現する。この理由として次の二つが
考えられる。一つは、菌によっであるいは、その代謝産
物によって生理機能を損傷された皮膚は、丘疹、びらん
などの病相を呈し、寄生性皮膚疾患治療薬として配合さ
れ九抗菌活性物質などの刺激性物に対して感受性が異常
に高くなっていることである。他の理由は、抗菌活性物
質が殺菌剤や防腐剤として配合された場合、その製品は
ベビー用品や化粧品であることが多く、敏感な皮膚への
使用をさけることができないことである。However, these antibacterial active substances are often accompanied by irritation when applied to the skin, and these irritations cause side effects such as skin disorders. There are two possible reasons for this. One is that skin whose physiological functions are damaged by bacteria or their metabolites exhibits pathological phases such as papules and erosions, and is formulated as a treatment for parasitic skin diseases. An abnormally high sensitivity to things. Another reason is that when antibacterial active substances are incorporated as disinfectants or preservatives, the products are often baby products or cosmetics, and their use on sensitive skin cannot be avoided.
このように抗菌活性物質はその刺激性による皮膚障害の
副作用をさけるためにその製剤ヘの配合濃度が制限され
る結果、最近増加している手、足等の寄生性皮膚疾患や
女性陰部の感染症等に対する治療は充分なものといえな
いのが現状である。In this way, the concentration of antibacterial active substances in formulations is restricted in order to avoid the side effects of skin damage due to their irritation, and as a result, the number of parasitic skin diseases on the hands and feet and infections of the female genitals that have recently increased. At present, treatment for these symptoms is not sufficient.
一方、抗菌活性物質は、その抗菌性に選択特異性を有す
ることが多い。すなわち、ウンデシレン酸、トルナフテ
ートなどの抗真菌剤として使用されている物質は糸状菌
に対してのみ抗菌作用を示し、ヘキサクロロフェンなど
の殺菌剤として使用されている物質は、黄色ブドウ球菌
、連鎖球菌などの細菌に対して抗菌作用を示す。On the other hand, antibacterial active substances often have selective specificity in their antibacterial properties. In other words, substances used as antifungal agents such as undecylenic acid and tolnaftate have an antibacterial effect only against filamentous fungi, and substances used as bactericidal agents such as hexachlorophene have an antibacterial effect against Staphylococcus aureus, Streptococcus, etc. Shows antibacterial activity against bacteria.
しかし、皮膚の損傷部分は常に二次感染の可能性をはら
んでおり、湿疹部が悪化してとびひ(水庖性膿癲疹)を
生じる例や、白癖症とカンシダ感染症さらに、湿疹と白
廚症など、複雑な合併症を発現する例は決して少なくな
い0
従って、低濃度でしかも広い範囲の菌に対して、有効な
抗菌活性を示す低刺激性の抗菌剤の開発が望まれていた
。However, damaged areas of the skin always have the possibility of secondary infection, and there are cases where eczema worsens and causes impetigo (impetigo varicella), albinism and cansida infection, and eczema. There are many cases in which complex complications such as leukocytosis occur. Therefore, it is desirable to develop a hypoallergenic antibacterial agent that exhibits effective antibacterial activity against a wide range of bacteria at low concentrations. was.
斯かる現状に鑑み、本発明者らは、これらの問題点を解
決すべく鋭意研究を1ねた結果、カミツレ有効成分の一
つであるビサボロールを他の抗菌活性物質と配合すれば
、ビサボロールおよび他の抗菌活性物質の抗菌活性が相
乗的に増強され、かつ当該他の抗菌活性物質の刺激性が
著しく減弱されることを見い出し、本発明を完成した。In view of the current situation, the present inventors conducted intensive research to solve these problems, and found that if bisabolol, one of the active ingredients of chamomile, is combined with other antibacterial active substances, bisabolol and The present invention was completed based on the discovery that the antibacterial activity of other antibacterial active substances is synergistically enhanced and the irritation of the other antibacterial active substances is significantly attenuated.
すなわち、本発明はビサボロール及び他の抗菌活性物質
を含有することを特徴とする抗菌剤組成物を提供するも
のである。That is, the present invention provides an antibacterial composition characterized by containing bisabolol and other antibacterial active substances.
本発明組成物に配合されるビサボロールは、カミツレの
精油及び?デラの葉芽中に含有さレルセスキテルペンア
ルコールであっテ、同じカミツレ油の抗炎症作用成分と
して古くから知られているアズレンの効力増強作用物質
研究の結果として見い出された化合物の一つである。ビ
サボロールは優れた抗炎症作用、抗潰瘍作用だけでなく
、白廖菌やカンジダなとの真菌類及びダラム陽性菌に対
する抗菌作用を有することが知られている。Bisabolol blended into the composition of the present invention includes chamomile essential oil and ? It is one of the compounds discovered as a result of research into the potency-enhancing agent of azulene, which has long been known as an anti-inflammatory component of chamomile oil. Bisabolol is known not only to have excellent anti-inflammatory and anti-ulcer effects, but also to have antibacterial effects against fungi such as Bacillus alba and Candida, and against Durum-positive bacteria.
本発明組成物には、実質的にビサボロールが配合されて
いればよく、単離されたビサボロールだけでなく、ビサ
ボロール含有植物抽出エキスとして配合されてもよい。The composition of the present invention only needs to contain substantially bisabolol, and may be blended not only as isolated bisabolol but also as a bisabolol-containing plant extract.
ビサボロール含有植物抽出エキスは、カミツレ、?デラ
、ミロカルブx (Myrocarpus fromd
osus Fr。Bisabolol-containing plant extract is chamomile,? Della, Myrocarpus x (Myrocarpus fromd.
osus Fr.
Allem)、ラベンダー(L、 officinal
is Chaix)、/%マヂンチョウ(Myopor
um Craasifolium )等の植物からエタ
ノール、エーテル、アセトン等の有機溶媒で抽出するこ
とにより得られる0またビサボロールを単離するKは、
これらの抽出物から水蒸気蒸留にて精油として回収した
後、例えば活性アルミナを担体としたクロマトグラフィ
ー等により分離するとエタノール溶出分画として得られ
る0なお、これらの植物から得られるビサボロールは、
α−ビサボロールとして得られるので、本発明において
はα−ピサゴロールを使用するのが好ましい0
本発明組成物に配合される他の抗菌活性物質としては、
主に外用において作用するもの、例、tばウンデシレン
酸、ウンデシレン酸亜鉛、サリチル酸、チアントール、
トルナフテート、クロトリマゾール、ナフチオメート、
ゾロピオン酸、カプリル酸、ペンタクロロフェノール、
サリチル酸8−ベンゾキシキノリン、トリクロルフェニ
ルヨードデロノ♀ギルエーテル、グリセオフルビン、バ
リオチン、ピロルニドリン、モクタール、イオウ、フェ
ニルヨードウンデジノエート、ハロゾロシン、トリコマ
イシン、バリオシン、ビロールニドリン、シツカニン、
ナイスタチン、エキサラミド、シクロビロクスオラミン
、アムホテリシンB1硝酸ミコナゾール、硝酸エコナゾ
ール、硝酸インコナゾール、トリメチルセチルアンモニ
ウムペンタクロロフェネート、酢酸ビスデカリーウム、
ジベンズチオン等の抗真菌剤:クロルキシレノール、塩
化ベンゼトニウム、インプロピルメチルフェノール、チ
モール、レゾルシン、塩化リソチーム、グルコン酸クロ
ルヘキシシン、オルトフェニルフェノール、ソルビン酸
、デヒドロ酢酸、次亜塩素酸ナトリウム、ヨウ素、ヨー
ドチンキ、ヨードホルム、?ビドンヨード、IQラオキ
シ安息香酸エチル、ノQラオキシ安息香酸プロピル、ホ
ウ酸、ホウ砂、オキジドール、過マンガン酸カリウム、
クロラミンT、クロルクレゾール、クロルフェネシン、
ホルマリン、フェノール、ヘキサクロ+27二ン、クレ
オソート、クロロブタノール、チオキソロン、チラム、
トリブロムサラン、塩化メチルロザリニン、塩化ベンザ
ルコニウム、ラウリル硫酸ナトリウム、尿素、塩酸アル
キル−リアミノエチルグリシン、イクタモール等が挙げ
られる。Allem), Lavender (L, official
is Chaix), /% Myopor
um Craasifolium) and other plants by extraction with organic solvents such as ethanol, ether, acetone, etc.
After recovering the essential oil from these extracts by steam distillation and separating it by chromatography using activated alumina as a carrier, it is obtained as an ethanol-eluted fraction.
Since it is obtained as α-bisabolol, it is preferable to use α-pisagoolol in the present invention.Other antibacterial active substances to be incorporated into the composition of the present invention include:
Those that mainly act externally, such as undecylenic acid, zinc undecylenate, salicylic acid, thianthol,
tolnaftate, clotrimazole, naphthiomate,
Zoropionic acid, caprylic acid, pentachlorophenol,
Salicylic acid 8-benzoxyquinoline, trichlorphenyl iododerono♀gyl ether, griseofulvin, variotin, pyrrolnidoline, moctal, sulfur, phenyl iodo undesinoate, halozolosin, trichomycin, variocin, virolnidoline, cytucanin,
Nystatin, exalamide, cyclovirox olamine, amphotericin B1 miconazole nitrate, econazole nitrate, inconazole nitrate, trimethylcetylammonium pentachlorophenate, bisdekarium acetate,
Antifungal agents such as dibenzthione: chlorxylenol, benzethonium chloride, inpropylmethylphenol, thymol, resorcinol, lysozyme chloride, chlorhexicine gluconate, orthophenylphenol, sorbic acid, dehydroacetic acid, sodium hypochlorite, iodine, iodotincture, iodoform ,? Bidon-iodine, IQ ethyl laoxybenzoate, no-Q propyl laoxybenzoate, boric acid, borax, oxidol, potassium permanganate,
Chloramine T, chlorcresol, chlorphenesin,
Formalin, phenol, hexachloro+272, creosote, chlorobutanol, thioxolone, thiram,
Examples include tribromusalan, methylrosalinine chloride, benzalkonium chloride, sodium lauryl sulfate, urea, alkyl-lyaminoethylglycine hydrochloride, ictamol, and the like.
本発明組成物を製造するには、ビサボロールが室温で油
状物質であり、はとんどの抗菌活性物質を溶解する特性
を有しているので、ビサボロールに他の抗菌活性物質を
溶解することKよって得られる。To prepare the composition of the invention, it is necessary to dissolve other antibacterial active substances in bisabolol, since bisabolol is an oily substance at room temperature and has the property of dissolving most antibacterial active substances. can get.
ビサボロールと他の抗菌活性物質の配合比は、ビサボロ
ール:他の抗菌活性物質=1000 :l〜1:200
がのぞましい。特に他の抗菌活性物質がウンデシレン酸
、サリチル酸、モクタール、フェニルヨードウンデジノ
エート、クロトリマゾール、ビロールニドリン、エキサ
ラミド、ハロゾロシン、シクロビロクスオラミン、クロ
ルキシレノール、イソプロピルメチルフェノール、チモ
ール、レゾルシン、オルトフェニルフェノール、/Qラ
オキシ安息香酸プロピル、クロルフェネシン、ラウリル
硫酸ナトリウム、ノQラオキシ安息香酸エチルなど、ビ
サボロールに対する相溶性が大きいものである場合は、
1 : 1−1 :200の配合比かのぞましい。また
これらのものが、化粧品、シャンプー等の防腐剤のよう
に製剤上微生物学的汚染防止を目的として配合される場
合にはl:l−1:10が特に好1しく、医薬品や医薬
部外品等の薬効成分として配合される場合には、1:2
0〜l: 200が特に好ましい。The blending ratio of bisabolol and other antibacterial active substances is bisabolol:other antibacterial active substances=1000:l~1:200
It's amazing. In particular, other antimicrobial active substances include undecylenic acid, salicylic acid, moctal, phenyl iodo undedinoate, clotrimazole, virolnidoline, exalamide, halozolosin, cycloviroxolamine, chlorxylenol, isopropylmethylphenol, thymol, resorcinol, orthophenylphenol, /Q Propyl benzoate, chlorphenesin, sodium lauryl sulfate, NoQ ethyl benzoate, etc., which have high compatibility with bisabolol,
A blending ratio of 1:1-1:200 is desirable. In addition, when these substances are blended for the purpose of preventing microbiological contamination in the formulation, such as preservatives in cosmetics and shampoos, the l:l-1:10 ratio is particularly preferred; When used as a medicinal ingredient in products, etc., the ratio is 1:2.
0-1: 200 is particularly preferred.
また、他の抗菌活性物質がウンデシレン酸亜鉛、トルナ
フテート、イオウ、シツカニン、ナイスタチン、硝酸ミ
コナゾール、硝酸エコナゾール、硝酸インコナゾール、
トリメチルセチルアンモニウムペンタクロロフェネート
、バリオチン、塩化リゾチーム、グルコン酸クロルヘキ
シシン、ヨウ素、ヨードチンキ、ホウ砂、塩化ベンザル
コニウム等、相溶性の小さいものである場合は、ビサボ
ロール:抗菌剤=looo : l−100: l
の配合比がのぞましい。この場合においても、微生物学
的汚染防止の目的としては、1000:l〜500:l
の配合比が特に好ましく、薬効成分としては200 :
1〜100:1が好ましい。In addition, other antibacterial active substances include zinc undecylenate, tolnaftate, sulfur, cytucanin, nystatin, miconazole nitrate, econazole nitrate, inconazole nitrate,
If the compatibility is low, such as trimethylcetylammonium pentachlorophenate, variotin, lysozyme chloride, chlorhexicine gluconate, iodine, iodine tincture, borax, benzalkonium chloride, etc., bisabolol: Antibacterial agent = loooo: l-100 : l
The blending ratio is desirable. In this case as well, for the purpose of preventing microbiological contamination,
A blending ratio of 200:
1 to 100:1 is preferred.
本発明組成物には、所望により他の消炎剤、ビタミン剤
、抗酸化剤、湿潤剤、収れん剤、鎮痒剤、副腎皮質ホル
モン剤、鎮痛剤、前記抗菌活性物質以外の抗生物質、サ
ルファ剤、香料、色材等を配合することができる。The composition of the present invention may optionally contain other anti-inflammatory agents, vitamins, antioxidants, humectants, astringents, antipruritics, adrenocortical hormones, analgesics, antibiotics other than the above-mentioned antibacterial active substances, sulfa drugs, and fragrances. , coloring materials, etc. can be blended.
本発明組成物は、その用途に応じて液剤、油剤、クリー
ム、乳液などの乳剤型、ノックダー等の粉剤、リニメン
ト剤、ノ♀スタ剤、油脂性軟膏剤、エアゾール、スプレ
ー、ノQツデ剤等とすることができる。これらの剤型と
する場合に用いられる基剤としては、エタノール、イソ
デロノQノールなどの低級アルコール、オリーブ油、部
分水添オリーブ油、アーモンド油、ホホバ油、落花生油
、ヤシ油、ノQ−ム油、サフラワー油、ひまわり油、綿
実油、硬化ヤシ油、硬化ノQ−ム油、アボガド油、ゴマ
油などの植物油および硬化油;タードル油、ガズセン、
ミンク油、スクワレン、プリスタン、ザマン、ラウラン
、牛脂、卵黄油などの動物油:鯨ロウ、セラック、ミツ
ロウ、ラノリン、液状ラノリン、還元ラノリン、硬質ラ
ノリン等の動物ロウ:カルナバロウ、キャンデリラロウ
などの植物性ロウ:流動ノQラフイン、流動ポリイソブ
チレン、α−オレフィンオリゴ1−、スクワラン、ワセ
リン、ノ9ラフイン、インノ♀ラフイン、流動イノノ9
ラフイン、オシケライト、セラック、トイクロクリスタ
リンワックス、ポリエチレン末などの炭化水素類:ラウ
リン酸、ミリスチン酸、ノqルミチン酸、ステアリン酸
、イソステアリン酸、オレイン酸、リノール酸、リシノ
ール酸、ベヘニン酸、ラノリン脂肪酸などの脂肪酸ニラ
ウリルアルコール、セタノール、2−へキシルドデカノ
ール、ステアリルアルコール、イソメf 71Jルアル
コール、オレイルアルコール、2−オクチルドデカノー
ル、ベヘニルアルコール、ラノリンアルコール、コレス
テロール、フィトステロール等の高級アルコール:エチ
レンクリコール、エチレングリコールモノアルキルエー
テル、ジエチレングリコールモノエチルエーテル、トリ
エチレングリコール、&lJエチレングリコール、テロ
ピレングリコール、?リデロビレングリコール、1,3
−プチレングリコール、グリセリン、破りグリセリン、
メチルアルコール、ペンタエリスリトール等の多価アル
コール類:アゾピン酸ゾイソデロビル、イソステアリン
酸へキシルデシル、イソオクタン酸セチル、オレイン酸
オレイル、オレイン酸デシル、酢酸ラノリン、ジメチル
オクタン酸へキシルデシル、ステアリン酸ブチル、セバ
シン酸ゾイソfロビル、トリオレイルリン酸、乳酸セチ
ル、乳酸ミリスチル、ノQルミチン酸インゾロビル、ミ
リスチン酸インプロピル、フタル酸ゾエチル、ミリスチ
ン改オクチルドデシル、ミリスチン& ミリスチル、ラ
ウリン緻ヘキシルなどのエステル類の他に、アルギン酸
プロピレングリコール、エチルセルロース、カルボキシ
メチルセル0−スナトリウム、ヒドロキシエチルセルロ
ース、ヒドロキシプロピルセルロース、メチルセルロー
ス、などの半合成高分子化合物:カルボキシビニルぼり
1−1?リアクリル酸ナトリウム、?リビニルアルコー
ル、?リピニルメチルエーテル、ポリビニルピロリドン
などの合成高分子化合物およびアニオン界面活性剤、カ
チオン界面活性剤、両性界面活性剤、非イオン界面活性
剤、などの乳化剤があげられる。The composition of the present invention can be used in emulsion forms such as liquids, oils, creams, and emulsions, powders such as knockers, liniments, nosters, oil-based ointments, aerosols, sprays, and no-Q tsude formulations, depending on the intended use. etc. Bases used in these formulations include lower alcohols such as ethanol and isoderono-Q-nol, olive oil, partially hydrogenated olive oil, almond oil, jojoba oil, peanut oil, coconut oil, gnome oil, Vegetable oils and hydrogenated oils such as safflower oil, sunflower oil, cottonseed oil, hydrogenated coconut oil, hydrogenated gnome oil, avocado oil, sesame oil; turdle oil, gazsen,
Animal oils such as mink oil, squalene, pristane, zaman, lauran, beef tallow, and egg yolk oil; Animal waxes such as spermaceti, shellac, beeswax, lanolin, liquid lanolin, reduced lanolin, and hard lanolin; Vegetable waxes such as carnauba wax and candelilla wax. Wax: Fluid No Q Rough In, Fluid Polyisobutylene, α-Olefin Oligo 1-, Squalane, Vaseline, No9 Rough In, Inno♀ Rough In, Fluid Inono 9
Hydrocarbons such as roughin, osikelite, shellac, toicrocrystalline wax, polyethylene powder: lauric acid, myristic acid, noqlumitic acid, stearic acid, isostearic acid, oleic acid, linoleic acid, ricinoleic acid, behenic acid, lanolin fatty acid Fatty acids such as nilauryl alcohol, cetanol, 2-hexyldodecanol, stearyl alcohol, isomeryl alcohol, oleyl alcohol, 2-octyldodecanol, behenyl alcohol, lanolin alcohol, cholesterol, higher alcohols such as phytosterols: ethylene glycol , ethylene glycol monoalkyl ether, diethylene glycol monoethyl ether, triethylene glycol, &lJ ethylene glycol, telopylene glycol, ? Riderobilene glycol, 1,3
-butylene glycol, glycerin, broken glycerin,
Polyhydric alcohols such as methyl alcohol and pentaerythritol: zoisoderovir azopic acid, hexyldecyl isostearate, cetyl isooctanoate, oleyl oleate, decyl oleate, lanolin acetate, hexyldecyl dimethyloctanoate, butyl stearate, zoiso f sebacate In addition to esters such as lovil, trioleyl phosphate, cetyl lactate, myristyl lactate, inzolovir rumitate, inpropyl myristate, zoethyl phthalate, myristin modified octyldodecyl, myristin & myristyl, and hexyl laurinate, propylene alginate Semi-synthetic polymer compounds such as glycol, ethyl cellulose, sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose, etc.: Carboxyvinyl 1-1? Sodium lyacrylate? Rivinyl alcohol? Examples include synthetic polymer compounds such as lipinyl methyl ether and polyvinylpyrrolidone, and emulsifiers such as anionic surfactants, cationic surfactants, amphoteric surfactants, and nonionic surfactants.
本発明組成物は、ビサボロール及び他ノ抗菌活性物質の
抗菌活性が相乗的に向上し、かつ他の抗菌活性物質の皮
膚刺激性が顕著に低下した優れた抗菌剤組成物である。The composition of the present invention is an excellent antibacterial agent composition in which the antibacterial activity of bisabolol and other antibacterial active substances is synergistically improved, and the skin irritation of other antibacterial active substances is significantly reduced.
従って、ダラム陽性菌(5taphyrococcus
aureua /黄色ブドウ球菌s 5taphyr
ococcus epidermis/表皮ブドウ球菌
、Bacillus 5ubutilis /枯草菌、
Propionibacterium acnes /
にきび桿菌)糸状914 (Trichophyton
mentagrophytos 7毛そう白癖菌、T
ricophyton ruburum 徨紅色白廖菌
Candidaalbicans鵞口そうカンシダ菌)
などが原因となる各種疾患に対し、低濃度で有効に治療
お゛よび予防することができる。また皮膚刺激性が低下
していることから、応用範囲が極めて広く、寄生性皮膚
疾患用架、殺菌消毒薬などの外皮用薬だけでなく、フケ
取り剤、ヘアトニック、シャンプー、リンス、などの毛
髪用剤、および口腔、粘膜、耳鼻咽喉、肛門、陰部など
の感染症に対する殺菌消毒薬や、感染予防を目的として
各種医薬部外品あるいは、化粧品等に使用することがで
きる。Therefore, Durham-positive bacteria (5 taphyrococcus
aureua / Staphylococcus aureus s 5taphyr
ococcus epidermis/Staphylococcus epidermidis, Bacillus 5ubutilis/Bacillus subtilis,
Propionibacterium acnes /
Acne bacillus) filamentous 914 (Trichophyton)
mentagrophytos 7. Mentagrophytos, T.
ricophyton ruburum Candidaalbicans)
Various diseases caused by such diseases can be effectively treated and prevented at low concentrations. In addition, because the skin irritation is reduced, the range of applications is extremely wide, not only for external skin medicines such as parasitic skin diseases and disinfectants, but also for dandruff removers, hair tonics, shampoos, conditioners, etc. It can be used in hair preparations, sterilizing disinfectants for infectious diseases of the oral cavity, mucous membranes, ear, nose and throat, anus, genitals, etc., and various quasi-drugs or cosmetics for the purpose of preventing infection.
次に実施例を挙げて本発明を説明する。 Next, the present invention will be explained with reference to Examples.
実施例1
α−ビサボロールとサリチル酸を各配合比率で混合し、
黄色ブドウ球菌、表皮ブドウ球菌またはくきび桿菌に対
する抗菌性を寒天培地法で測定した。なお、α−ビサボ
ロールは、30%エタノール溶液として、サリチル酸は
、トリエタノールアミンで中和したエタノール−水(1
:l )10%溶液として用いた。Example 1 α-bisabolol and salicylic acid were mixed at various blending ratios,
The antibacterial activity against Staphylococcus aureus, Staphylococcus epidermidis, or Bacillus acnes was measured by the agar culture method. Note that α-bisabolol was prepared as a 30% ethanol solution, and salicylic acid was prepared as a 30% ethanol solution, and salicylic acid was prepared as a 30% ethanol solution.
:l) Used as a 10% solution.
方゛法 プレインハートインフュージョン22.2t。method Plain Heart Infusion 22.2t.
寒天9?に脱イオン水6007dを加え、100℃の温
浴中で溶解した。溶凄した4天溶液を1001ntの三
角フラスコに50−ずつ分注した。Agar 9? 6007d of deionized water was added to the solution and dissolved in a 100°C hot bath. The four melted solutions were dispensed into 1001 nt Erlenmeyer flasks in 50 portions.
これをオートクレーブで15分間滅菌し、約60分間放
置した。その後、約50℃の温浴上に放置した。This was sterilized in an autoclave for 15 minutes and left for about 60 minutes. Thereafter, it was left in a hot bath at about 50°C.
得られた寒天培地に試料溶液を滴下し、各フラスコをそ
れぞれ超音波で攪拌し、その後滅菌シャーレに静かに流
しこみ、1昼夜室温中に放置した。あらかじめ種培養を
しておいた菌を、各培地に無菌的に接種し、37℃で1
〜5日間培養し、菌の増殖の有無を測定した0
なお、にきび桿菌の抗菌性試験は、CAM培地を用い、
上記と同様の操作で行った。The sample solution was added dropwise to the obtained agar medium, each flask was stirred using ultrasonic waves, and then gently poured into a sterilized Petri dish and left at room temperature for one day and night. Bacteria that had been seed cultured in advance were aseptically inoculated into each medium, and incubated at 37°C for 1 hour.
The culture was cultured for ~5 days and the presence or absence of bacterial growth was measured.
The same procedure as above was performed.
結果
試験結果より、α−ビサボロールとサリチル酸の各配合
比における各画に対する最小発育阻止濃度(MIC)
を求め、第1図K、縦軸にα−ビサボロール濃度、横
軸にサリチル酸濃度をとったMIC曲線として表わした
。その結果、第1図から明らかにα−ビサボロールとサ
リチル酸の混合系は顕著な相乗効果を示した。Results From the test results, the minimum inhibitory concentration (MIC) for each plot at each blending ratio of α-bisabolol and salicylic acid.
was determined and expressed as an MIC curve in FIG. 1K, with α-bisabolol concentration on the vertical axis and salicylic acid concentration on the horizontal axis. As a result, it is clear from FIG. 1 that the mixed system of α-bisabolol and salicylic acid showed a remarkable synergistic effect.
実施例2 α−ビサボロールとへキサクロロフェンヲ。Example 2 α-Bisabolol and hexachlorophene.
各配合比率で混合し、狸紅色白!JI菌、毛そう白癖菌
またはカンシダ菌に対する抗菌性を実施例1と同様にし
て寒天培地法で測定した。Mix with each blending ratio to create a raccoon red and white color! The antibacterial properties against JI bacteria, P. albicans, and C. cansida were measured using the agar culture method in the same manner as in Example 1.
なお、ヘキサクロロフェンは、30ラエタノール溶液と
して用いた。Note that hexachlorophene was used as a 30-mL ethanol solution.
その結果、第2図に示す如く、α−ビサボロールとへキ
サクロロフェンの混合系は、すべての菌に対し顕著な相
乗効果を示した。As a result, as shown in FIG. 2, the mixed system of α-bisabolol and hexachlorophene showed a remarkable synergistic effect against all bacteria.
実施例3
白色ワセリン 250
ステアリルアルコール 220ゾロピレングリ
コール 120ラウリル硫酸ナトリウム
15.0α−ビサボロール 3.0
精製水 全量100.Of白色ワセリンと
ステアリルアルコールヲ熔融し、75℃に保つ。ラウリ
ル硫酸ナトリウムを加温し、これに10ピレングリコー
ルを加えて混和する。これに熔融物を加え、ホモミキサ
ーで50′cKなるまで攪拌後放冷してα−ビサボロー
ル及びラウリル硫酸ナトリウムを含有する病原性湿疹用
軟膏を得た。Example 3 White petrolatum 250 Stearyl alcohol 220 Zoropylene glycol 120 Sodium lauryl sulfate
15.0 α-Bisabolol 3.0 Purified water Total amount 100. Melt white petrolatum and stearyl alcohol and keep at 75°C. Heat sodium lauryl sulfate, add 10 pyrene glycol and mix. The melt was added thereto, stirred with a homomixer until it reached 50' cK, and then allowed to cool to obtain an ointment for pathogenic eczema containing α-bisabolol and sodium lauryl sulfate.
実施例4
コレステロール 309
ステアリルアルコール 30?ミツロウ
80?
クロルキシレノール 0.2tカミツレエキ
ス 2?
白色ワセリン 全量1000?ステアリルアル
コール、ミツロウ、白色ワセリン、クロルキシレノール
およびカミツレエキス(α−ビサボロールとして約10
119含有)を加温してよくかきまぜ、これにコレステ
ロールを加えて完全に溶けるまでかきまぜて放冷し、α
−ビサボロールおよびクロルキシレノールを含有する水
虫用軟膏を得た。Example 4 Cholesterol 309 Stearyl alcohol 30? Beeswax
80? Chlorxylenol 0.2t Chamomile extract 2? White Vaseline total amount 1000? Stearyl alcohol, beeswax, white petrolatum, chlorxylenol and chamomile extract (approximately 10% as α-bisabolol)
119 (containing), stir well, add cholesterol to this, stir until completely dissolved, leave to cool,
- An athlete's foot ointment containing bisabolol and chlorxylenol was obtained.
第1図は、実施例1Kかけるα−ビサボロールとサリチ
ル酸混合系の各画に対するMIC曲線、第2図は実施例
2におけるα−ビサボロールとへキサクロo7エン混合
系の各画に対するMIC曲線をそれぞれ示す図面である
。
以上
第 1 図
ヶ+)flに酸 01(匍FIG. 1 shows the MIC curve for each fraction of the mixed system of α-bisabolol and salicylic acid multiplied by Example 1K, and FIG. 2 shows the MIC curve for each fraction of the mixed system of α-bisabolol and hexachloro-o7ene in Example 2. It is a drawing. Above is Figure 1. Add acid to fl.
Claims (1)
を特徴とする抗菌剤組成物。1. An antibacterial composition containing bisabolol and other antibacterial active substances.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61177968A JPS6333326A (en) | 1986-07-29 | 1986-07-29 | Antibacterial composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP61177968A JPS6333326A (en) | 1986-07-29 | 1986-07-29 | Antibacterial composition |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS6333326A true JPS6333326A (en) | 1988-02-13 |
Family
ID=16040226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP61177968A Pending JPS6333326A (en) | 1986-07-29 | 1986-07-29 | Antibacterial composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS6333326A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0348560A1 (en) * | 1987-05-11 | 1990-01-03 | Lion Corporation | Oral composition |
EP0420630A2 (en) * | 1989-09-27 | 1991-04-03 | Colgate-Palmolive Company | Antiplaque oral compositions |
US8241681B2 (en) * | 2005-10-14 | 2012-08-14 | Symrise Ag | Synergistic mixtures of bisabolol and ginger extract |
JP2013501782A (en) * | 2009-08-12 | 2013-01-17 | コルゲート・パーモリブ・カンパニー | Oral care composition |
JP2013256481A (en) * | 2012-06-14 | 2013-12-26 | La Shinshia Kk | Antimicrobial agent and cosmetic |
WO2017223181A1 (en) * | 2016-06-24 | 2017-12-28 | Colgate-Palmolive Company | Oral care composition and method of use |
-
1986
- 1986-07-29 JP JP61177968A patent/JPS6333326A/en active Pending
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0348560A1 (en) * | 1987-05-11 | 1990-01-03 | Lion Corporation | Oral composition |
EP0420630A2 (en) * | 1989-09-27 | 1991-04-03 | Colgate-Palmolive Company | Antiplaque oral compositions |
GR900100713A (en) * | 1989-09-27 | 1992-01-20 | Colgate Palmolive Co | Oral compositions against tooth decay |
US8241681B2 (en) * | 2005-10-14 | 2012-08-14 | Symrise Ag | Synergistic mixtures of bisabolol and ginger extract |
JP2013501782A (en) * | 2009-08-12 | 2013-01-17 | コルゲート・パーモリブ・カンパニー | Oral care composition |
US8906349B2 (en) | 2009-08-12 | 2014-12-09 | Colgate-Palmolive Company | Oral care composition |
US9889077B2 (en) | 2009-08-12 | 2018-02-13 | Colgate-Palmolive Company | Oral care composition |
JP2013256481A (en) * | 2012-06-14 | 2013-12-26 | La Shinshia Kk | Antimicrobial agent and cosmetic |
WO2017223181A1 (en) * | 2016-06-24 | 2017-12-28 | Colgate-Palmolive Company | Oral care composition and method of use |
US10335615B2 (en) | 2016-06-24 | 2019-07-02 | Colgate-Palmolive Company | Oral care compositions and methods of use |
US10773105B2 (en) | 2016-06-24 | 2020-09-15 | Colgate-Palmolive Company | Oral care compositions and methods of use |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2241894C (en) | Use of octoxyglycerin in a cosmetic and/or dermatological composition as active agent for the treatment of seborrhoea and/or acne | |
US20080070875A1 (en) | Acne treatment compositions and methods of use | |
EP2566488B1 (en) | Povidone-iodine topical composition | |
JPH10509437A (en) | Deodorant, antimicrobial and preservative compositions and methods of using them | |
JPS59108716A (en) | Antiacne composition | |
JP2693859B2 (en) | Acne vulgaris skin external preparation for acne | |
JPH1077222A (en) | Combination of active compound having activity against bacterium, fungus and virus and based on partial glyceride and dialkyl substituted acetic acid | |
FR2748937A1 (en) | USE OF ALPHA-ALKLYGLUCOSIDES AND ALPHA-ALKYLGLUCOSIDE ESTERS AS ANTI-MICROBIAL EMULSIFYING AGENTS | |
JP2011074082A (en) | Antiseptic sterilizer and composition for application to human body | |
JP2937667B2 (en) | Skin external preparation for acne vulgaris | |
JPH10182346A (en) | Cosmetic | |
JPS6333326A (en) | Antibacterial composition | |
JPH03178916A (en) | Skin external agent | |
JPS62126128A (en) | External preparation composition | |
JP2700070B2 (en) | Antimicrobial agent for Gram-positive anaerobic bacteria, external preparation for skin and oral composition using the same | |
JP4220769B2 (en) | Anti-acne bacteria composition | |
JPH11302147A (en) | Cosmetic | |
JP2941241B2 (en) | Preservatives and cosmetic or pharmaceutical compositions containing them | |
JP2000302674A (en) | Selective antibacterial composition | |
JPH10203991A (en) | Preparation for external use for skin | |
JPH10298095A (en) | Antibacterial agent | |
JP2020525482A (en) | Antibacterial mixture containing 4-(3-ethoxy-4-hydroxyphenyl)butan-2-one and chlorphenesin, and cosmetic composition containing the same | |
JP2807792B2 (en) | External preparation for skin | |
EP3648735A1 (en) | Novel use | |
JP2002332237A (en) | External preparation for skin |